|
|
|
|
Onyx Pharmaceuticals Acquires Option to License Novel Highly Specific JAK2 Inhibitors From S*BIO
EMERYVILLE, Calif.'JAK2 is implicated across a broad range of difficult-to-treat illnesses, including cancer and autoimmune diseases, and is one of the most exciting potential new targets in cancer therapy today. These compounds fit...
|
|
|
Thrombocytopenia consequences highlighted for ACS patients
MedWire News: Acute coronary syndrome (ACS) patients who develop thrombocytopenia have a greater risk for a poor outcome than those who do not, GRACE study findings demonstrate.Regardless of whether this occurred in the setting of...
|
|
|
Onyx Pharmaceuticals Acquires Option to License Novel Highly Specific JAK2 Inhibitors From S*BIO
'JAK2 is implicated across a broad range of difficult-to-treat illnesses, including cancer and autoimmune diseases, and is one of the most exciting potential new targets in cancer therapy today.These compounds fit with our vision of...
|
|
|
Onyx Pharmaceuticals Acquires Option to License Novel Highly
EMERYVILLE, Calif.'JAK2 is implicated across a broad range of difficult-to-treat illnesses, including cancer and autoimmune diseases, and is one of the most exciting potential new targets in cancer therapy today. These compounds fit...
|
|
|
(12/4) FDA approves GSKs Promacta for patients with chronic ITP
GSK also launches Promacta Cares, an information resource for patients and healthcare professionals GlaxoSmithKline announced November 20, that the FDA granted accelerated approval for Promacta (eltrombopag) for the treatment of ...
|
|
|
Oxygen Bio responds to US FDA on phase 2 trial of Oxycyte in TBI
Oxygen Biotherapeutics, Inc has filed a response to the FDA's request for information and that the filing also includes a synopsis of the company's revised protocol for a phase-II dose escalation clinical trial of Oxycyte in Traumatic Brain...
|
|
|
The incidence of heparin-induced thrombocytopenia Type II in patients with subarachnoid hemorrhage treated wit
You can also purchase online an Individual or Institutional Subscription to this journal or buy one or more printed volumes.The incidence of heparin-induced thrombocytopenia Type II in patients with subarachnoid hemorrhage treated...
|
|
|
[Neurooncology] Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Pr
Purpose: To evaluate single-agent activity of bevacizumab in patients with recurrent glioblastoma.Patients and Methods: Patients with recurrent glioblastoma were treated with bevacizumab 10 mg/kg every 2 weeks. After tumor progression,...
|
|
|
Oxygen Biotherapeutics, Inc. Submits Information Package to FDA
-Oxygen Biotherapeutics, Inc.(OTCBB:OXBO) today announced that the company has filed a response to the FDAs request for information and that the filing also includes a synopsis of the companys revised protocol for a Phase II dose...
|
|
|
Canine babesiosis (Proceedings)
Canine babesiosis is a tick-borne disease caused by a hemoprotozan parasite belonging to the order Piroplasmida within the phylum Apicomplexa.Historically, two Babesia spp. were known to infect dogs, and these were morphologically...
Thomson Veterinary Healthcare Communications:
Dec 24 2008 9:25PM
Matching: thrombocytopenia
|
Find similar documents
|
|
|
|
Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic co
Arkenau H-T et al.- In a meta-analysis to compare the efficacy of capecitabine (CAP)/oxaliplatin (OX) with infusional fluorouracil (FU)/OX, it was shown that combination CAP/OX resulted in lower response rate (RR), but this did not affect...
|
|
|
Celgene International Sarl: Promising results from 2 trials highlighting pomalidomide presented at ASH
Promising results from 2 trials highlighting pomalidomide presented at ASH (NewsRx.com) -- BOUDRY, Switzerland--(December 10, 2008)--Celgene International Sarl (Nasdaq: CELG) announced that its next IMiDs compound, pomalidomide, has shown...
|
|
|
Ligand inks new development pact with Glaxo
San Diego-based Ligand Pharmaceuticals will pocket a $5 million upfront fee and up to $158 million in development and commercial milestones under a new pact it signed with GlaxoSmithKline covering its experimental platelet-booster and other...
|
|
|
Rare MI risk highlighted for thrombocytopenia patients
MedWire News: Patients with multiple thrombotic risk factors should be carefully monitored following thrombocytopenia treatment, US clinicians recommend.In a case report published in the Journal of Clinical Rheumatology, the team...
|
|
|
Bevacizumab treatment in multifocal lymphangioendotheliomatosis with thrombocytopenia
Kline RM et al.- Multifocal lymphangioendotheliomatosis with thrombocytopenia (MLT) is a rare disorder characterized by a proliferation of cutaneous and gastrointestinal (GI) lesions that have characteristics of both lymphatic and...
|
|
|
Oxygen Biotherapeutics, Inc. Submits Information Package to FDA
- Oxygen Biotherapeutics, Inc.(OTCBB:OXBO) today announced that the company has filed a response to the FDAs request for information and that the filing also includes a synopsis of the companys revised protocol for a Phase II dose...
|
|
|
Oxygen Biotherapeutics, Inc. Submits Information Package to FDA
Oxygen Biotherapeutics, Inc.(OTCBB:OXBO) today announced that the company has filed a response to the FDAs request for information and that the filing also includes a synopsis of the companys revised protocol for a Phase II dose...
|
|
|
Oxygen Biotherapeutics, Inc. Submits Information Package to FDA
Includes Oxycyte Clinical Trial Protocol Summary COSTA MESA, Calif.--(BUSINESS WIRE)--Dec 23, 2008 - Oxygen Biotherapeutics, Inc.(OTCBB:OXBO) today announced that the company has filed a response to the FDA's request for information and...
|
|
|
European Commission Grants Vidaza Full Marketing Authorization for the Treatment of Patients with Higher-Risk
Celgene International Srl (Nasdaq:CELG) today announced that its cancer drug, VIDAZA (azacitidine), has been granted full marketing authorization by the European Commission for the treatment of adult patients who are not eligible for...
|
|
|
Celgene Gets European Commission Marketing Approval For Cancer Drug Vidaza - Update
Tuesday, Celgene Corp.(CELG: News ), said its cancer drug candidate, Vidaza, has been granted full marketing authorization by the European commission for treating adult patients with Intermediate-2 and Higher-Risk Myelodysplastic...
|
|
|
Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis smal
S M Lee1, L E James2, W Qian3, S Spiro1, T Eisen4, N H Gower2, D R Ferry5, D Gilligan6, P G Harper7, J Prendiville7, M Hocking8, R M Rudd9 1 University College Hospital, London, UK 2 Cancer Research UK & University College London...
|
|
|
Ligand licenses worldwide rights to LGD-4665 & thrombopoietin molecules to GSK
Ligand Pharmaceuticals Incorporated has entered into an exclusive, worldwide license agreement with GlaxoSmithKline (GSK) under which Ligand has licensed worldwide exclusive rights to Ligand's LGD-4665 product candidate and its other...
|
|
|
Thrombolysis tolerated by elderly PE patients
MedWire News: Thrombolysis is well tolerated by elderly patients with massive pulmonary embolism (PE), Italian researchers have found.Giovanni Gallotta ('Federico II' University, Naples) and co-workers say their results confirm that age...
|
|
|
A phase I study of Triapine® in combination with doxorubicin in patients with advanced solid tumors
20 pts received a total of 49 courses of treatment on study.At dose level 2 (doxorubicin 60 mg/m2, Triapine 45 mg/m2), 2 pts experienced DLTs (febrile neutropenia, grade 4 thrombocytopenia). An additional 3 pts were enrolled at...
|
|
|
Ligand Pharmaceuticals Inc executes license agreement with GlaxoSmithKline for LGD-4665
Ligand Pharmaceuticals Inc (NASDAQ:LGND), which discovers and develops new drugs that address critical unmet medical needs, said on 18 December that the company has signed an exclusive, worldwide license agreement with GlaxoSmithKline (GSK) ...
|
